5-hydroxytryptamine1A (5-HT1A) receptor agonists: A decade of empirical evidence supports their use as an efficacious therapeutic strategy for brain trauma.
5-hydroxytryptamine1A (5-HT1A) receptor agonists: A decade of empirical evidence supports their use as an efficacious therapeutic strategy for brain trauma.
复制标题
DOI：
10.1016/j.brainres.2015.11.026
复制
发表时间：
2016-06-01
期刊：
影响因子：
2.9
通讯作者：
Kline AE
中科院分区：
文献类型：
--
作者：
Cheng JP;Leary JB;Sembhi A;Edwards CM;Bondi CO;Kline AE
创伤性脑损伤（TBI）是一个重要而持久的医疗保健问题，治疗方案有限。虽然一些临床前治疗方法已经导致运动和/或认知能力的增强，但这些治疗的好处还没有转化为临床。一种合理的解释是，这些疗法可能没有经过严格的评估，因此导致从实验室到临床的飞跃过早，随后也不成功。在脑外伤后进行大量实证研究的一种方法是用激动剂如盐酸雷匹诺坦、8-羟基-2-（二正丙基氨基）四氢萘林（8-OH-DPAT）和丁螺环酮等药物靶向5-HT1A受体。本综述的目的是整合和解释一系列研究的结果，这些研究评估了5-HT1A受体激动剂对获得性脑损伤后功能、组织学和分子结局的影响。这份详尽的综述的压倒性共识是，十年的经验证据支持它们作为一种有效的脑外伤治疗策略。
Traumatic brain injury (TBI) is a significant and enduring health care issue with limited treatment options. While several pre-clinical therapeutic approaches have led to enhanced motor and/or cognitive performance, the benefits of these treatments have not translated to the clinic. One plausible explanation is that the therapies may not have been rigorously evaluated, thus rendering the bench-to-bedside leap premature and subsequently unsuccessful. An approach that has undergone considerable empirical research after TBI is pharmacological targeting of 5-HT1A receptors with agonists such as repinotan HCl, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), and buspirone. The goal of this review is to integrate and interpret the findings from a series of studies that evaluated the efficacy of 5-HT1A receptor agonists on functional, histological, and molecular outcome after acquired brain injury. The overwhelming consensus of this exhaustive review is that a decade of empirical evidence supports their use as an efficacious therapeutic strategy for brain trauma.